VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$7.67
0.19 (2.54%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 09, 2026
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 2.8% growth. Moderate conviction.
💡 BUY OPPORTUNITY: VMD shows positive signals but monitor for confirmation. Market pricing in 2.8% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.43
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.34
8.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $7.67, which is considered extended relative to its 30-day fair value range of $7.25 to $7.47. The stock's valuation (Forward PE: 13.1) is in line with its historical norms (12.1). At these levels, the market is pricing in 2.8% annual earnings growth.
Technical Outlook: Technically, VMD is in a strong uptrend. The price is approaching resistance at $7.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+73.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VMD is in a strong uptrend. The price is approaching resistance at $7.65. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+73.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$7.25 -
$7.47
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 73.8% below Wall St target ($13.00)
- BULLISH: Expecting earnings turnaround to 2.8% growth with 24.0% revenue growth
Fair Price Analysis
30-Day Fair Range
$7.25 -
$7.47
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.34
(4.4%)
Support & Resistance Levels
Support Level
$7.19
Resistance Level
$7.65
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
13.12
Wall Street Target
$13.00
(+73.8%)
Revenue Growth (YoY)
24.0%
Earnings Growth (YoY)
-9.8%
Profit Margin
5.3%
Valuation Premium vs History
+2.8% premium
PE vs Historical
13.1 vs 12.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$7.69
(+3%)
2-Year Target
$7.90
(+6%)
3-Year Target
$8.13
(+9%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$7.49
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 43.7%)
$37.71
(+404%)
Base:
(SPY PE: 13.1, Growth: 43.7%)
$22.19
(+197%)
Bear:
(PE: 11.2, Growth: 43.7%)
$18.86
(+152%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 21.71 | Current EPS (TTM): $0.34
Bull Case
$13.61
(+77%)
Analyst growth 67.6%, PE expands to 23.9
Base Case
$12.37
(+61%)
Market implied 67.6%, PE stable at 21.7
Bear Case
$5.02
(-35%)
Severe decline -20.0%, PE contracts to 18.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 1:04 AM ET
Data refreshes hourly during market hours. Next update: 2:04 AM
Data refreshes hourly during market hours. Next update: 2:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jerome Cambre
SELL
4880 shares
2025-08-13
Michael Moore
SELL
50090 shares
2025-08-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$427 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
Advanced VMD Option Strategies
Professional options setups generated by AI based on today's VMD price and gamma walls.
